Overview

Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
This study will assess the safety and tolerability of multiple doses of VAK694 as well as change in symptoms and biomarkers in patients with seasonal allergic rhinitis
Phase:
Phase 2
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Fluticasone
Criteria
Inclusion Criteria:

- Male and female subjects between ages of 18 to 60 in good health

- History of atopy for at least 2 years and positive skin prick test to ragweed allergen

Exclusion criteria:

- History of asthma treated with corticosteroids

- Smokers with a smoking history of > 10 pack/years or smoking in the past year

- History of chronic obstructive pulmonary disease

Other protocol-defined inclusion/exclusion criteria may apply